Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development
Saved in:
| Published in: | Biologics: Targets & Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1864030190784479237 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Biologics: Targets & Therapy |
| description | |
| discipline_display | Natural Sciences |
| discipline_facet | Natural Sciences |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:18858 |
| institution | FRELIP |
| journal_source_facet | Biologics: Targets & Therapy |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development Biology Natural Sciences — Life Sciences Natural Sciences |
| sub_discipline_display | Natural Sciences — Life Sciences |
| sub_discipline_facet | Natural Sciences — Life Sciences |
| subject_display | Biology Natural Sciences — Life Sciences Natural Sciences Biology Natural Sciences — Life Sciences Natural Sciences |
| subject_facet | Biology Natural Sciences — Life Sciences Natural Sciences |
| title | Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development |
| title_auth | Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development |
| title_full | Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development |
| title_fullStr | Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development |
| title_full_unstemmed | Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development |
| title_short | Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development |
| title_sort | net present value impact of fda’s phase 3 waivers on monoclonal antibody biosimilar development |
| topic | Biology Natural Sciences — Life Sciences Natural Sciences |
| url | https://www.dovepress.com/net-present-value-impact-of-fdas-phase-3-waivers-on-monoclonal-antibod-peer-reviewed-fulltext-article-BTT |